Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | iStopMM study – the impact of nationwide screening

Sigurdur Kristinsson • 12 May 2022
COMy 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma
iStopMM

Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, shares some insights into the iStopMM study (NCT03327597), which is looking at early detection, and therefore early intervention in patients with smoldering multiple myeloma (SMM). The study aims to minimize the incidence of myeloma in Iceland with the hope of treating patients to prevent them from developing myeloma in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Gelgene, Amgen

More from Sigurdur Kristinsson

2:47
iStopMM analysis results: autoimmune diseases are not associated with MGUS
Sigurdur Kristinsson • 12 Dec 2022
1:51
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma
Sigurdur Kristinsson • 12 Dec 2022
2:21
Epidemiology, characteristics and detection of transient M proteins in the iStopMM study
Sigurdur Kristinsson • 12 Dec 2022
1:36
Multivariate model to predict the need for bone marrow sampling in patients with MGUS
Sigurdur Kristinsson • 12 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals